VU scientists' startup Revalida seeks capital, C-level team | Eva Marie Harth, Harth Group, biotechnology, nanotechnology, Vanderbilt University, Vanderbilt University Medical Center, technology transfer, commercialization, research and development, science, chemistry, pharmacology, pharmaceuticals, cancer, healthcare, medicine, life sciences, Alice van der Ende, David Calkins, Vanderbilt Eye Institute,
{}